secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001628280-24-045054
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025
-------------------------------------------------------------------------------

- CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.
- CMS concluded Caldolor does not qualify because FDA indication lacks mention of post-operative use.
- Company submitted comments in July 2023 and July 2024 arguing Caldolor meets statutory requirements.
- Company says majority of Caldolor use is surgical and FDA approval based on post-surgical pain studies.
- Cumberland is evaluating options; calls CMS determination inconsistent with NOPAIN Act intent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/0001628280-24-045054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/cpix-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer